rss
Ann Rheum Dis 71:1143-1150 doi:10.1136/annrheumdis-2011-200387
  • Clinical and epidemiological research
  • Extended report

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

Open Access
  1. David Fiorentino7
  1. 1Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA
  2. 2Division of Rheumatology, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA
  3. 3Inflammation and Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA
  4. 4Global Biostatistical Science, Amgen Inc, Thousand Oaks, California, USA
  5. 5Department of Biostatistics, KForce Clinical Research, Tampa, Florida, USA
  6. 6General Medicine and Inflammation Therapeutic Area, Amgen Inc, Thousand Oaks, California, USA
  7. 7Department of Dermatology, Stanford University, Palo Alto, California, USA
  1. Correspondence to Vibeke Strand, Division of Immunology/Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA; vstrand{at}stanford.edu
  • Received 30 June 2011
  • Accepted 7 December 2011
  • Published Online First 17 January 2012

Abstract

Objectives To compare health-related quality of life (HRQoL) before and after treatment with etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis using spydergram representations.

Methods Data from randomised, controlled trials of etanercept in patients with RA, PsA and psoriasis were analysed. HRQoL was assessed by the medical outcomes survey short form 36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores. Baseline comparisons with age and gender-matched norms and treatment-associated changes in domain scores were quantified using spydergrams and the health utility SF-6D measure.

Results Mean baseline PCS scores were lower than age and gender-matched norms in patients with RA and PsA, but near normative values in patients with psoriasis; MCS scores at baseline were near normal in PsA and psoriasis but low in RA. Treatment with etanercept resulted in improvements in PCS and MCS scores as well as individual SF-36 domains across all indications. Mean baseline SF-6D scores were higher in psoriasis than in RA or PsA; clinically meaningful improvements in SF-6D were observed in all three patient populations following treatment with etanercept.

Conclusions Patients with RA, PsA and psoriasis demonstrated unique HRQoL profiles at baseline. Treatment with etanercept was associated with improvements in PCS and MCS scores as well as individual domain scores in patients with RA, PsA and psoriasis.

Footnotes

  • Funding These analyses were funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009.

  • Competing interests ViS has been a consultant to Abbott Immunology, Alder Biopharmaceuticals, Amgen, BiogenIdec, Bristol-Myers Squibb, CBio, CanFite, Centocor, Chelsea Therapeutics, Emergent Biosolutions, Genentech, GlaxoSmithKline, Idera, Incyte, Iroko, Lexicon Genetics, Nuon Therapeutics, Pfizer, Regeneron, Rigel, Roche, Sanofi-Aventis, Schering Plough and UCB. VeS and DF have no conflicts to declare. ASK is an employee and shareholder of Pfizer Inc. GP, YS and DJZ are employees and shareholders of Amgen Inc. BW is a consultant for Amgen Inc.

  • Ethics approval Approval was obtained from the institutional review boards at all study sites.

  • Provenance and peer review Not commissioned; externally peer reviewed.

This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl